SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending as it hits new all-time highs, fueled by optimism surrounding its robotaxi initiatives despite some concerns about sales and earnings. The stock's momentum has sparked discussions about its valuation, potential short squeezes, and the broader implications of autonomous driving technology, with many traders expressing strong bullish or bearish sentiments.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation around its potential acquisition of Warner Bros. Discovery, with community discussions focusing on whether Netflix will increase its offer to compete with Paramount.  Some traders believe Netflix is oversold, while others anticipate further declines depending on the deal's outcome; the community is closely watching for official news and potential market reactions.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amid a hostile takeover bid for Warner Bros. Discovery ($WBD), challenging Netflix's ($NFLX) deal and sparking community debate about the best outcome. Discussions revolve around the financial implications, regulatory hurdles, and potential influence of figures like Trump and Ellison on the deal's outcome, with many viewing PSKY's all-cash offer as superior.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

PLCE is trending due to reactions to its earnings report and financial results, with discussions centering on the company's future prospects and potential bankruptcy. The community is actively debating the impact of revenue decreases, cost-saving measures, and a recent CEO appointment, with some speculating on a possible buyout or short squeeze. Overall sentiment is mixed, with bulls hoping for a turnaround and bears pointing to financial challenges.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to a recent surge, with community members drawing comparisons to SMX and emphasizing its potential in the robotics sector. The primary focus is on maintaining upward momentum, battling perceived short sellers, and removing stop losses. Speculation about a potential short squeeze and high after-hours targets are driving significant interest.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

DBV Technologies - ADR

DBV Technologies

DBV Technologies ($DBVT) is trending due to positive Phase 3 trial data for its Viaskin Peanut patch in toddlers, showing promising results in treating peanut allergies. The community is discussing the potential for accelerated FDA approval and the patch's impact on the peanut allergy market, with some highlighting the unmet need for effective treatments and the potential for significant revenue. However, concerns remain around potential dilution and cash runway.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

LEN is trending due to mixed reactions to earnings, with an EPS miss overshadowed by a revenue beat and positive Q3 outlook. The community is focused on the impact of affordability issues, mortgage rates, and the company's forward guidance. Discussions also involve broader market factors and analyst ratings.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending as the community discusses the potential impact of evolving government healthcare policies, particularly Affordable Care Act subsidies. Community members are analyzing the potential outcomes of current debates in the House and Senate, with some speculating on whether an extension of subsidies is likely. Bullish investors are optimistic about Centene's long-term prospects irrespective of near-term policy decisions.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the community discusses its recent AI and Autonomy Day, highlighting the company's advancements in self-driving technology and in-house chip development. The news has sparked debates around Rivian's competitive positioning against Tesla and the potential for a future robotaxi service, while some express concerns over cash burn and the timeline for profitability.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending amid speculation that cannabis rescheduling news could be imminent, possibly driven by Trump's upcoming address, igniting bullish sentiment. The community is buzzing about potential gains, anticipating institutional investment and significant sector transformation if rescheduling occurs, although some express concern over potential dilution. Overall, the prevailing sentiment is one of excitement and anticipation for potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Temas Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance

Tema ETFs (Tema), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (CANC) has surpassed $100m in assets under management (AUM) two...

Be Thankful to These ETFs This Year 

Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.

<ul class="summary-bullets"><li>Aucatzyl will be available through routine commissioning by the NHS, the company said.</li><li>Aucatzyl was approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024.</li><li>The company also intends to launch Aucatzyl in England and Wales soon, It added.</li></ul> Autolus Therapeutics Plc (AUTL) said on Tuesday that the UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending its Aucatzyl CAR T cell therapy for use in the National Health Service (NHS) in England and WalesShares of the company rose 14% in the premarket session at the time of writing.<h2 class="st-heading-2">UK Approval And Recommendation</h2>NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/nice-recommends-aucatzylr-obecabtagene-autoleucel-treatment">said</a>. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia is a cancer that either returns after treatment or never responded to initial therapy.Aucatzyl will be available through routine commissioning by the NHS, the company said. The company also intends to launch Aucatzyl in England and Wales soon, it added.Aucatzyl or obecabtagene autoleucel is an autologous CD19 CAR T cell therapy. Autologous CD19 CAR T-cell therapy is an immunotherapy that uses a patient's own T-cells, which are genetically modified to target and attack cells that express the CD19 protein. This treatment has shown high efficacy in relapsed or refractory B-cell malignancies.The U.S. Food and Drug Administration approved Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024. A conditional marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) followed in April 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AUTL stayed within the ‘bearish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘normal’ levels.A Stocktwits user sees the stock hitting as high as $2.50.<stembedurl>https://stocktwits.com/nader_1/message/637361441</stembedurl>Another applauded the recent announcement and expressed hope that cell therapy would become the standard of care.<stembedurl>https://stocktwits.com/janed102/message/637360741</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by 47% this year and by about 58% over the past 12 months. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-keys-stock-surge-14-in-premarket-today/cL52hzFREX8">Why Did KEYS Stock Surge 14% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 

Equity

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Tema ETF Trust - Tema Oncology ETF

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

CANC
Tema Oncology ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CANC News

CANCTema Oncology ETF